ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, except in the U.S., Australia, New Zealand, Japan, and China In August, the FDA approved ARS Pharmaceuticals' Neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients Neffy is also approved in Europe. Submission for regulatory approval in Canada is planned for by the end of 2024. ARS Pharma is also developing its intranasal adrenaline (epinephrine) technology for acute flares in patients with chronic urticaria, with plans to begin a Phase 2b trial in 2025. The license agreement gives ALK exclusive rights for new indications in the licensed territories. ALK will initially focus on bringing Neffy to Europe and Canada, the world's second and third-largest adrenaline autoinjector markets. In both markets, the product can be added to ALK's existing infrastru
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United StatesGlobeNewswire
- ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming ConferencesGlobeNewswire
- ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm Accesswire
SPRY
Earnings
- 11/13/24 - Miss
SPRY
Sec Filings
- 11/13/24 - Form 4
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- SPRY's page on the SEC website